Theratechnologies Inc. (TH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theratechnologies Inc. (TH) has a cash flow conversion efficiency ratio of -0.095x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.66 Million ≈ $1.92 Million USD) by net assets (CA$-27.92 Million ≈ $-20.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Theratechnologies Inc. for the company's overall valuation and market capitalisation.
Theratechnologies Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theratechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theratechnologies Inc. ranked by their cash flow conversion efficiency. Explore Theratechnologies Inc. (TH) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silver X Mining Corp
V:AGX
|
0.051x |
|
Waterco Ltd
AU:WAT
|
0.044x |
|
ReposiTrak
NYSE:TRAK
|
0.041x |
|
Walchandnagar Industries Limited
NSE:WALCHANNAG
|
0.034x |
|
Dexxos Participações S.A
SA:DEXP3
|
0.115x |
|
Saniona AB
ST:SANION
|
-0.125x |
|
PHA Co. Ltd
KQ:043370
|
0.033x |
|
Eastern Communications Co Ltd B
SHG:900941
|
0.030x |
Annual Cash Flow Conversion Efficiency for Theratechnologies Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of Theratechnologies Inc. from 1996 to 2024. View Theratechnologies Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | CA$-25.27 Million ≈ $-18.28 Million |
CA$2.38 Million ≈ $1.72 Million |
-0.094x | -134.60% |
| 2023-11-30 | CA$-20.87 Million ≈ $-15.10 Million |
CA$-5.68 Million ≈ $-4.11 Million |
0.272x | -58.20% |
| 2022-11-30 | CA$-22.57 Million ≈ $-16.33 Million |
CA$-14.69 Million ≈ $-10.63 Million |
0.651x | +179.85% |
| 2021-11-30 | CA$17.76 Million ≈ $12.85 Million |
CA$-14.48 Million ≈ $-10.47 Million |
-0.815x | +80.61% |
| 2020-11-30 | CA$3.22 Million ≈ $2.33 Million |
CA$-13.55 Million ≈ $-9.80 Million |
-4.204x | -2978.87% |
| 2019-11-30 | CA$24.83 Million ≈ $17.96 Million |
CA$-3.39 Million ≈ $-2.45 Million |
-0.137x | -1331.40% |
| 2018-11-30 | CA$35.05 Million ≈ $25.36 Million |
CA$-334.40K ≈ $-241.90K |
-0.010x | -116.76% |
| 2017-11-30 | CA$33.51 Million ≈ $24.24 Million |
CA$1.91 Million ≈ $1.38 Million |
0.057x | -43.11% |
| 2016-11-30 | CA$20.02 Million ≈ $14.48 Million |
CA$2.00 Million ≈ $1.45 Million |
0.100x | -71.72% |
| 2015-11-30 | CA$14.98 Million ≈ $10.83 Million |
CA$5.30 Million ≈ $3.83 Million |
0.354x | +134.63% |
| 2014-11-30 | CA$6.87 Million ≈ $4.97 Million |
CA$-7.02 Million ≈ $-5.08 Million |
-1.022x | -144.46% |
| 2013-11-30 | CA$17.45 Million ≈ $12.62 Million |
CA$-7.29 Million ≈ $-5.28 Million |
-0.418x | +39.39% |
| 2012-11-30 | CA$22.82 Million ≈ $16.51 Million |
CA$-15.74 Million ≈ $-11.39 Million |
-0.690x | +7.92% |
| 2011-11-30 | CA$35.20 Million ≈ $25.46 Million |
CA$-26.36 Million ≈ $-19.07 Million |
-0.749x | -1459.83% |
| 2010-11-30 | CA$51.65 Million ≈ $37.36 Million |
CA$2.84 Million ≈ $2.06 Million |
0.055x | -58.09% |
| 2009-11-30 | CA$40.70 Million ≈ $29.44 Million |
CA$5.35 Million ≈ $3.87 Million |
0.131x | +114.60% |
| 2008-11-30 | CA$37.80 Million ≈ $27.35 Million |
CA$-34.03 Million ≈ $-24.62 Million |
-0.900x | -83.28% |
| 2007-11-30 | CA$65.94 Million ≈ $47.70 Million |
CA$-32.39 Million ≈ $-23.43 Million |
-0.491x | +5.50% |
| 2006-11-30 | CA$38.96 Million ≈ $28.18 Million |
CA$-20.25 Million ≈ $-14.65 Million |
-0.520x | -487.37% |
| 2005-11-30 | CA$41.96 Million ≈ $30.35 Million |
CA$-3.71 Million ≈ $-2.69 Million |
-0.088x | +74.68% |
| 2004-11-30 | CA$53.02 Million ≈ $38.35 Million |
CA$-18.53 Million ≈ $-13.40 Million |
-0.349x | -6.85% |
| 2003-11-30 | CA$64.48 Million ≈ $46.65 Million |
CA$-21.09 Million ≈ $-15.26 Million |
-0.327x | -72.10% |
| 2002-11-30 | CA$79.51 Million ≈ $57.52 Million |
CA$-15.11 Million ≈ $-10.93 Million |
-0.190x | -58.13% |
| 2001-11-30 | CA$70.95 Million ≈ $51.32 Million |
CA$-8.53 Million ≈ $-6.17 Million |
-0.120x | -1.33% |
| 2000-11-30 | CA$38.53 Million ≈ $27.87 Million |
CA$-4.57 Million ≈ $-3.31 Million |
-0.119x | +40.93% |
| 1999-11-30 | CA$16.91 Million ≈ $12.23 Million |
CA$-3.40 Million ≈ $-2.46 Million |
-0.201x | +38.66% |
| 1998-11-30 | CA$10.94 Million ≈ $7.91 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.327x | +35.81% |
| 1997-11-30 | CA$7.03 Million ≈ $5.08 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.510x | -102.72% |
| 1996-11-30 | CA$11.80 Million ≈ $8.54 Million |
CA$-2.97 Million ≈ $-2.15 Million |
-0.252x | -- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more